PHOTOFRIN® (porfimer sodium) IS INDICATED FOR

Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy.

Treatment of microinvasive endobronchial non–small cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated.

Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC.

PHOTOFRIN® (porfimer sodium) is indicated for the ablation of high-grade dysplasia (HGD) in Barrett’s esophagus patients who do not undergo esophagectomy.

IMPORTANT SAFETY INFORMATION ABOUT PHOTOFRIN FOR INJECTION

Photodynamic therapy (PDT) with PHOTOFRIN is a two-stage process requiring administration of both drug and light in a properly equipped facility. Refer to the OPTIGUIDE® instructions for use for complete instructions concerning the fiber optic diffuser.

PHOTOFRIN is contraindicated in patients with porphyria. PDT is contraindicated in patients with an existing tracheoesophageal or bronchoesophageal fistula and patients with tumors eroding into a major blood vessel. PDT is not suitable for emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion because 40 to 50 hours are required between injection with PHOTOFRIN and laser light treatment. PDT is not suitable for patients with esophageal or gastric varices, or patients with esophageal ulcers >1 cm in diameter.

Tracheoesophageal or bronchoesophageal fistula can occur if esophageal tumor is eroding into trachea or bronchial tree. Gastrointestinal perforation can occur. There is a high risk of bleeding in patients with esophageal varices and for fatal massive hemoptysis with endobronchial tumors that are: large, centrally located; cavitating; extensive, extrinsic to the bronchus. After treatment of high-grade dysplasia (HGD) in Barrett’s esophagus (BE), monitor endoscopic biopsy every three months, until four consecutive negative evaluations for HGD have been recorded. Photosensitivity can be expected; ocular sensitivity is possible. Allow 2-4 weeks between PDT and subsequent radiotherapy. Substernal chest pain may occur after treatment. Treatment-induced inflammation can cause airway obstruction. Administer with caution to patients with tumors in locations where treatment-induced inflammation can obstruct the main airway. Esophageal stenosis occurs frequently after treatment of HGD in BE. Patients with hepatic or renal impairment may need longer precautionary measures for photosensitivity (possibly more than 90 days). Thromboembolic events can occur following photodynamic therapy with PHOTOFRIN.

MOST COMMON ADVERSE REACTIONS reported during clinical trials are:

**Esophageal Cancer:** Anemia, pleural effusion, pyrexia, constipation, nausea, chest pain, pain, abdominal pain, dyspnea, photosensitivity reaction, pneumonia, vomiting, insomnia, back pain, pharyngitis.

**Obstructing Endobronchial Cancer:** Dyspnea, photosensitivity reaction, hemoptysis, pyrexia, cough, pneumonia.

**Superficial Endobronchial Tumors:** Exudate, photosensitivity reaction, bronchial obstruction, edema, bronchostenosis.

**High-Grade Dysplasia in Barrett’s Esophagus:** Photosensitivity reaction, esophageal stenosis, vomiting, chest pain, nausea, pyrexia, constipation, dysphagia, abdominal pain, pleural effusion, dehydration.

Inform patients to report adverse reactions. All patients who receive PHOTOFRIN will be photosensitive for at least 30 days and should be warned about this and counselled to take appropriate precautions. Laser treatment should not be given if an overdose of PHOTOFRIN is administered.

FOR MORE INFORMATION ABOUT PHOTOFRIN visit www.Photofrin.com or call Concordia Laboratories Inc. at 1-877-370-1142.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full prescribing information for PHOTOFRIN.
Photodynamic Therapy (PDT) Is a Guideline-Recommended Endobronchial Therapy

PDT is one of the most studied endobronchial treatment modalities.

PDT IN DIFFERENT STAGES OF NON–SMALL CELL LUNG CANCER (NSCLC)
- It is one of the modalities for definitive therapy for carcinoma in situ and microinvasive (superficial) NSCLC
- Symptomatic management Stage I or II
- Can be used for induction for Stage IIIA or IIIB
- Palliation

THERAPY FOR RECURRENCE

The 3 Components of Photodynamic Therapy (PDT)

1. PHOTOFRIN® (porfimer sodium)
PHOTOFRIN (porfimer sodium) is injected 40-50 hours prior to laser activation and is selectively retained in tumor cells. When activated with red laser light, the drug produces a chain reaction of cell death in targeted tissue.

2. FIBER
The OPTIGUIDE® Diffuser Series features a range of fibers for reaching the tumor and delivering red laser light for PHOTOFRIN activation. The Diffuser Series includes the rigid DCYL200 series and the DCYL700 series, featuring new flexible-yet-durable material to ease navigation through instruments and anatomy.

3. LASER
The laser generates red light with a wavelength of 630 nm to activate PHOTOFRIN.

* See Principles of Surgical Therapy (NSCL-B).
† See Principles of Radiation Therapy (NSCL-C).

References quoted may have used settings not within the prescribing information for PHOTOFRIN® (porfimer sodium).
Typically used in an outpatient setting, PHOTOFRIN (porfimer sodium) is reconstituted and administered as a single IV injection over 3 to 5 minutes.

Photosensitizer is selectively retained in cancer cells.

Red light permeates tissue (the indicated light dosimetry for endobronchial cancer is 200 J/cm) and activates PHOTOFRIN to an excited state.†

Energy transfer generates reactive singlet oxygen‡ and selective necrosis of the target lesion up to a 6-mm depth.§

Excited PHOTOFRIN causes vasoconstriction, which leads to vascular occlusion and additional tumor cell death.¶

Treatment results in lysis and ischemic necrosis of cancer cells.¶ Cleanout bronchoscopy is performed to remove obstructive debris.

Removal of post treatment necrotic tissue.

An OPTIGUIDE® Fiber Optic Diffuser is used to administer 630 nm nonthermal light.

Excited PHOTOFRIN (porfimer sodium) causes vasoconstriction, which leads to vascular occlusion and additional tumor cell death.¶
PDT Makes Selective Treatment of Target Lesions and Tumor Margins Possible Up to a Depth of 6 mm

Photodynamic therapy (PDT) provides depth of ablation—up to 6 mm.

**ESTIMATED DEPTH OF DAMAGE FOR VARIOUS METHODS OF ENDOSCOPIC MUCOSAL ABLATION**

<table>
<thead>
<tr>
<th>Method of ablation</th>
<th>Approximate depth of ablation (mm)</th>
<th>Author/ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argon laser (514 nm)</td>
<td>0.3</td>
<td>Weston 2003</td>
</tr>
<tr>
<td>KTP laser (532 nm)</td>
<td>0.4</td>
<td>Dix 1996</td>
</tr>
<tr>
<td>Diode laser (805 nm)</td>
<td>1.3</td>
<td>Dix 1996</td>
</tr>
<tr>
<td>Nd:YAG laser (1064 nm)</td>
<td>4–6</td>
<td>Dix 1996</td>
</tr>
<tr>
<td>APC (30–90 W)</td>
<td>1–3</td>
<td>Barham 1996; Franchimont 2003</td>
</tr>
<tr>
<td>MPEC 15–20 W</td>
<td>1.7–4.8</td>
<td>Sampliner 2003</td>
</tr>
<tr>
<td>ALA PDT</td>
<td>2</td>
<td>Tan 1999; Gossner 1990</td>
</tr>
<tr>
<td>Exogenous PDT</td>
<td>4–6</td>
<td>Barr 1990; Heier 1995</td>
</tr>
<tr>
<td>Cryotherapy</td>
<td>1–4</td>
<td>Johnston 2003</td>
</tr>
</tbody>
</table>

KTP, potassium titanyl phosphate; Nd:YAG, neodymium yttrium aluminium garnet; APC, argon beam plasma coagulation; MPEC, multipolar electrocoagulation; ALA PDT, 5-aminolevulinic acid photodynamic therapy.

**TUMOR RESPONSE AND ATELECTASIS IMPROVEMENT**

<table>
<thead>
<tr>
<th>Efficacy parameter</th>
<th>PDT N=102, % patients</th>
<th>Nd:YAG N=109, % patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective tumor response†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 1</td>
<td>59%</td>
<td>58%</td>
</tr>
<tr>
<td>Month 1 or later</td>
<td>60%</td>
<td>41%*</td>
</tr>
<tr>
<td>Atelectasis improvement‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 1</td>
<td>35%</td>
<td>18%</td>
</tr>
<tr>
<td>Month 1 or later</td>
<td>35%</td>
<td>20%</td>
</tr>
</tbody>
</table>

† Statistical comparisons were precluded by the amount of missing data at Month 1 or later (i.e., for tumor response, PDT 28% missing, Nd:YAG 38%).
‡ CR+PR where CR=complete response (absence of bronchoscopically visible tumor) and PR=partial response (increase of ≥50% in the smallest luminal diameter, or any appearance of a lumen for completely obstructing tumors).

In patients with atelectasis at baseline.

**EXTENDED SURVIVAL AND SYMPTOM IMPROVEMENT COMPARED TO ND:YAG LASER RESECTION**

Fourteen patients out of 31 with late-stage obstructing endobronchial cancer who were treated with PHOTOFRIN® (porfimer sodium) PDT achieved:

- Post treatment survival was significantly longer in the PDT group than in the Nd:YAG laser resection group: 265 days PDT, 95 days Nd:YAG, P=0.007.
- Similar improvement in dyspnea, cough, hemoptysis symptoms and sputum production in both groups.
### Benefits of Photodynamic Therapy (PDT)

**IMPROVED PERFORMANCE STATUS AND RESPIRATORY FUNCTION**

Stage IIIA-IV Symptom Palliation in Patients With Advanced Inoperable Bronchogenic and Endobronchial Luminal Obstruction

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Pre PDT Mean±SD</th>
<th>Post PDT Mean±SD</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Obstruction</td>
<td>85.8±19.6</td>
<td>18.5±17.3</td>
<td>-67.3%</td>
</tr>
<tr>
<td>(% Range)</td>
<td>(30-100)</td>
<td>(0-35)</td>
<td></td>
</tr>
<tr>
<td>FVC (1) L</td>
<td>2.07±0.78</td>
<td>2.50±0.74</td>
<td>+0.43 L</td>
</tr>
<tr>
<td>FEV1 (1) L</td>
<td>2.07±0.78</td>
<td>2.50±0.74</td>
<td>+0.43 L</td>
</tr>
<tr>
<td>WHO ≤2</td>
<td>N=43</td>
<td>N=87</td>
<td>+44</td>
</tr>
<tr>
<td>WHO &gt;2†</td>
<td>N=54</td>
<td>N=10</td>
<td>-44</td>
</tr>
</tbody>
</table>

WHO performance status scores summary
- 0: Asymptomatic
- 1: Symptomatic but completely ambulatory
- 2: Symptomatic, <50% in bed during the day
- 3: Symptomatic, >50% in bed, but not bedbound
- 4: Bedbound
- 5: Death

44 patients (81% of WHO >2) move to WHO ≤2

* Study was prospective nonrandomized.
† In 3 patients, pretreatment WHO was recorded as between 2 (Symptomatic, <50% in bed during the day) and 3 (Symptomatic, >50% in bed, but not bedbound).

---

### Multimodality Treatment With Photodynamic Therapy (PDT)

**SEQUENCE AND TIMING OF THERAPIES**

<table>
<thead>
<tr>
<th>PDT in combination with</th>
<th>Induction/ Preoperative</th>
<th>Concurrent</th>
<th>Adjuvant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nd:YAG/APC</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Radiation therapy (XRT, EBRT, SBRT, brachytherapy)</td>
<td>X</td>
<td>X</td>
<td>2-4 weeks if PDT is used prior to radiation†</td>
</tr>
<tr>
<td>Surgery</td>
<td>X</td>
<td>X</td>
<td>Allow 10-12 weeks post PDT for surgical intervention‡</td>
</tr>
</tbody>
</table>

**Comments relating to PDT**
- PDT may be beneficial when utilized after Nd:YAG or APC to further enhance local control.
- Avoid overlapping toxicities.
- Ensure/confirm blood cell count normal.
- The timing of PDT is ideal before radiotherapy because of its potential impact on vascular access.
- Avoid overlapping toxicities.
- Ensure/confirm blood cell count normal.
- Allow 10-12 weeks post PDT for surgical intervention.

*PHOTOFRIN® (porfimer sodium) prescribing information does not include reference to PDT use in conjunction with other treatment modalities besides radiotherapy.

References quoted may have used settings not within the prescribing information for PHOTOFRIN® (porfimer sodium).
Radiation Treatment and Photodynamic Therapy (PDT)

PDT MAY BE USED WITH RADIATION THERAPY (XRT), WHICH MAY PROVIDE ADDITIONAL BENEFITS

Patients With Inoperable Non–Small Cell Bronchogenic Carcinoma Obstructing a Central Airway

Complete Reopening of Bronchial Lumen With No Residual Tumor

Complete reopening of the bronchial lumen with no gross tumor visible on bronchoscopy was observed in 2 of 21 patients (10%) in the XRT group and 14 of 20 patients (70%) in the PDT+XRT group at 1 and 3 months after treatment ($P<0.05$).

There were no treatment failures in the PDT+XRT group, but 4 of 21 (19%) patients in the XRT group failed to respond to treatment.

Interval Between Treatment and Local Recurrence

The median interval between treatment and local recurrence was significantly longer in the PDT+XRT group than in the XRT group (233 days vs 107 days, $P=0.005$).

Palliation of hemoptysis and shortness of breath was significantly better for the PDT+XRT group 3 months after treatment, along with reduction in cough at 1 and 3 months.

Median Time to Local Recurrence

The median time to local recurrence was significantly longer in the PDT+XRT group than in the XRT group (233 days vs 107 days, $P=0.005$).

References


10. PDT Academy: Faculty recommendation; 2015.

Pinnacle Biologics™ Support

Pinnacle Biologics™ offers a comprehensive suite of programs and services to support your practice and patients.

**FOR YOUR PRACTICE**

- On-site assistance to help establish the use of photodynamic therapy (PDT) in your facility
- PDT Laser support
- PDT Academy certification
- Insurance benefit verification
- Reimbursement and billing support

**FOR YOUR PATIENTS**

- Patient education materials
- Patient co-pay assistance
- Referral to independent nonprofit co-pay foundations
- Patient assistance program

Visit www.PHOTOFRIN.com or call 1-855-215-2720 to learn more.

PHOTOFRIN® (porfimer sodium) and OPTIGUIDE® are registered trademarks of Concordia Laboratories Inc.
Pinnacle Biologics™ and the logo of Pinnacle Biologics™ are trademarks of Pinnacle Biologics, Inc.
PHOTOFRIN® is manufactured by Jubilant Hollisterstier General Partnership for Concordia Laboratories Inc. and distributed in the United States by Pinnacle Biologics, Inc.
Concordia Laboratories Inc. St. Michael, Barbados BB11005
See more at: http://www.photofrin.com/healthcare-professional-home/#sthash.FInUv0e7.dpuf.
If there are any questions regarding the information provided, please contact Concordia’s Medical Information Department at 1-877-370-1142.

PINMAR011 02/2016 All rights reserved.